Phase 2 Metastatic Castration-resistant Prostate Cancer trials recruiting now

All Metastatic Castration-resistant Prostate Cancer trials, every phase

Other phases for Metastatic Castration-resistant Prostate Cancer

Phase 2 Metastatic Castration-resistant Prostate Cancer trials

• 64Cu-GRIP B in Patients With Advanced Malignancies
  NCT05888532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
  NCT07005154 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 54 locations
• A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06842498 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 23 locations
• A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT06533644 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 23 locations
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 160 locations
• A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
  NCT06155084 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 27 locations
• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07287150 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 48 locations
• A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
  NCT05125016 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 14 locations
• ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
  NCT07414940 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
  NCT05113537 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
  NCT05413850 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 21 locations
• Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
  NCT06738303 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06401980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 13 locations
• Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
  NCT05762536 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
  NCT05521412 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
  NCT06480110 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
  NCT05766371 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
  NCT07476001 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
  NCT05720130 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
  NCT06971211 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
  NCT06100705 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
  NCT05489211 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 96 locations
• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
  NCT07288359 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
  NCT06866938 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 16 locations
• Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
  NCT06228053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 6 locations
• Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
  NCT07142551 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• The COSMYC Trial (COmbined Suppression of MYC)
  NCT06922318 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
  NCT06972628 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06568562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
  NCT04986423 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 31 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.